Investor Relations
Company Overview
X4 is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. X4’s pipeline is comprised of first-in-class, oral, small molecule antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies, neutropenia, and certain cancers.
Jan 20, 2021 6:29 AM EST
Copyright West LLC.
Minimum 15 minutes delayed.
Refresh Quote
Copyright West LLC.
Minimum 15 minutes delayed.
Press Releases
January 19, 2021
January 7, 2021
January 4, 2021
Events
Jan 20, 2021 at 11:00 AM EST
Jan 11, 2021 at 6:00 AM EST
Nov 16, 2020 at 8:40 AM EST
Presentations
X4 Pharmaceuticals Corporate Presentation January 2021
X4 Pharma Post-EHA Corporate Update Presentation
2020 Analyst Day Webinar: A Deep Dive into WHIM Syndrome